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Abstract
The analysis of chromosomal abnormalities is important for the study
of hematological neoplastic disorders since it facilitates classification
of the disease. The ability to perform chromosome analysis of cryopre-
served malignant marrow or peripheral blast cells is important for
retrospective studies. In the present study, we compared the karyotype
of fresh  bone marrow cells (20 metaphases) to that of cells stored with
a simplified cryopreservation method, evaluated the effect of the use
of granulocyte-macrophage colony-stimulating factor (GM-CSF) as
an in vitro mitotic index stimulator, and compared the cell viability
and chromosome morphology of fresh and cryopreserved cells when-
ever possible (sufficient metaphases for analysis). Twenty-five bone
marrow samples from 24 patients with hematological disorders such
as acute myeloid leukemia, acute lymphoblastic leukemia, myelodys-
plastic syndrome, chronic myeloid leukemia, megaloblastic anemia
and lymphoma (8, 3, 3, 8, 1, and 1 patients, respectively) were selected
at diagnosis, at relapse or during routine follow-up and one sample
was obtained from a bone marrow donor after informed consent.
Average cell viability before and after freezing was 98.8 and 78.5%,
respectively (P < 0.05). Cytogenetic analysis was successful in 76% of
fresh cell cultures, as opposed to 52% of cryopreserved samples (P <
0.05). GM-CSF had no proliferative effect before or after freezing.
The morphological aspects of the chromosomes in fresh and cryopre-
served cells were subjectively the same. The present study shows that
cytogenetic analysis of cryopreserved bone marrow cells can be a
reliable alternative when fresh cell analysis cannot be done, notwith-
standing the reduced viability and lower percent of successful analysis
that are associated with freezing.
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The analysis of chromosomal abnormali-
ties is extremely important for the diagnosis
of hematological neoplastic disorders since
it facilitates the classification of the disease
as recommended by the World Health Or-
ganization Classification of Tumors of He-
matopoietic and Lymphoid Tissues (1). In
addition, it is fundamental for prognosis and
helps monitoring residual disease and the
occurrence of relapse or clonal evolution.
Cytogenetic studies involve the examina-
tion of mitotic cells and therefore require
spontaneously dividing bone marrow cells
or even circulating blasts in peripheral blood.
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However, karyotype results cannot be ob-
tained in all cases since the main problem in
chromosomal analysis and karyotyping is a
low mitotic index in some samples or fuzzy
chromosomes sometimes not analyzable.
Many efforts have been made in order to
increase the mitotic index using conditioned
media derived from solid tumor cell lines
that contain growth factors, granulocyte-
macrophage colony-stimulating factor (GM-
CSF) or recombinant interleukin 3, although
with poor results (2,3).
In fact, the ability to perform chromo-
some analysis of cryopreserved malignant
marrow or peripheral blast cells is important
for retrospective studies or for storing addi-
tional material. This procedure could even
provide enough time to determine a final
morphological or immunophenotypic diag-
nosis of disease subtype while chromosome
analysis is performed and could contribute
to the decision about patient treatment and
care. But the most important feature is that
frozen cells are easily transported from re-
mote facilities to experienced centralized
cytogenetic laboratories for more detailed
chromosomal analysis.
Reports that describe culturing of cryo-
preserved cells are helpful but show that the
procedure is not as good as culturing fresh
samples (2-4). The use of thawed cryopre-
served cells has gained wide acceptance in
routine clinical practice and in many areas of
research such as immunohematology, trans-
plantation and molecular biology (5).
The aim of the present study was to com-
pare the karyotype of fresh bone marrow
cells and cells preserved with a simplified
cryopreservation method and to evaluate the
effects of the use of GM-CSF as an in vitro
mitotic index stimulator.
Twenty-five bone marrow samples from
24 patients with hematological disorders were
selected at diagnosis, at relapse or during
routine follow-up and one sample was ob-
tained from a bone marrow donor after in-
formed consent. Table 1 shows the diagnosis
by FAB (6) and REAL (7) classification and
the stage of the disease at the time of sample
collection.
Fresh bone marrow cells were isolated
with a Ficoll-Hypaque (Sigma, St. Louis,
MO, USA) gradient and divided into two
parts, one for cryopreservation and the other
for fresh short-term cell culture.
The cells were cultivated as previously
reported for chromosome analysis (8).
Briefly, the cells were separated into two
short-term cultures with 7 ml RPMI 1640,
pH 7.0, 3 ml fetal calf serum (Sigma), 100 µl
Table 1. Patient diagnosis and mitotic index data obtained for each pre- and post-
freezing culture and cryopreservation period.
Case Diagnosis Mitotic index Duration of
Pre-freezing Post-freezing cryopreservation
GM-CSF GM-CSF
- + - +
1 CML 6.3 7.0 2.3 3.0 12 days
2 CML 5.3 7.3 3.0 2.0 16 days
3 BM donor 4.7 6.7 1.7 2.0 35 days
4 CML 0 2.0 0.3 0.3 45 days
5 AML-M4 0.7 0.3 0 0 3 months
6 AML post-BMT* 1.0 1.3 1.0 1.7 3 months
7 MDS 1.3 3.0 0.3 1.0 3 months
8 ALL-T* 5.0 6.0 0 0 3 months
9 ALL-T 1.0 2.3 0.7 0.3 3 months
10 AML-M2* 0.7 2.3 0 0 3 months
11 Lymphoma 0.3 0.3 0.3 0 3 months
12 MDS 0 0 0 0 3 months
13 AML-M2 1.7 1.3 0 0.3 3 months
14 AML-M7 0.3 1.7 1.3 2.3 3 months
15 CML-BC 0 0 0 0 3 months
16 CML 3.7 9.3 0.3 2.3 3 months
17 ALL in remission 0.7 2.7 0 0 3 months
18 CML 0.7 3.0 0.7 0 3 months
19 Megaloblastic anemia 1.3 3.0 3.0 1.3 4 months
20 AML in remission 0.7 2.0 0.0 0.3 4 months
21 MDS 1.7 3.0 0.3 0.7 4 months
22 AML-M3 1.0 1.3 0 0 4 months
23 AML-M2* 1.0 2.3 0.3 0.3 4 months
24 CML 1.7 2.7 0 0.3 4 months
25 CML 4.0 2.7 0.3 0.3 4 months
Bone marrow cells were cultured in the presence (+) or absence (-) of 0.1 µg/ml
granulocyte-macrophage colony-stimulating factor (GM-CSF). Mitotic index data are
reported as the mean of three independent determinations. ALL, acute lymphoblastic
leukemia; AML, acute myeloid leukemia; BC, blast crisis; BM, bone marrow; BMT,
bone marrow transplantation; CML, chronic myeloid leukemia; MDS, myelodysplastic
syndrome. * = Relapse.
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L-glutamine (2 mM, Synthy®, São Paulo,
SP, Brazil) and incubated for 24 h at 37ºC.
Seven microliters GM-CSF (100 ng/ml)
(Leucomax®, Sandoz S.A., Basel, Switzer-
land) was added to one of the culture flasks
for 24 h (culture B). Colcemid (50 µl) was
added to both culture flasks for the final 30
min, followed by 75 mM KCl at room tem-
perature for 20 min and Carnoy’s fixative for
5 min, four times. Slides were prepared and
submitted to G banding and whenever pos-
sible at least 15 metaphases were analyzed
(range: 0-38) and the abnormalities described
according to ISCN 1995 (9).
The cryopreservation method was the
same as used by Zaroulis (10). Cells were
cryopreserved in Normosol R (Abbott Labo-
ratories, Chicago, IL, USA) with 12% hy-
droxyethyl starch (Sigma), 8% human serum
albumin and 10% dimethylsulfoxide (DMSO;
Sigma). This cryoprotectant solution was
added to bone marrow cells at a final con-
centration of 6% hydroxyethyl starch, 4%
human serum albumin and 5% DMSO. The
vials were frozen at -80ºC and stored for 12,
16, 35 and 45 days in 4 cases, and at least 3
months in 21 cases. After the freezing pe-
riod, the cells were rapidly thawed in a 37ºC
water bath and diluted with RPMI 1640 me-
dium corresponding to three times the total
bone marrow volume. Two cultures were
then set up exactly the same way as for fresh
cells. Cell viability was tested in all samples
before and after freezing and the method
described by Regidor et al. (11) was used to
compare the results. Statistical analysis was
Table 2. Pre- and post-freezing karyotypes.
Case Pre-freezing No. of metaphases Post-freezing No. of metaphases
obtained obtained
1 46,XX,t(9;22)(q34;q11) 15 46,XX,t(9,22)(q34;q11) 6
2 46,XX,t(9;22)(q34;q11) 15 46,XX,t(9,22)(q34;q11) 7
3 46,XY 13 46,XY 7
4 46,XY,t(9;22)(q34;q11) 13 No result 4
5 No result 9 No metaphase 0
6 No result 36 No result 10
7 46,XX 15 No result 16
8 46,XX/49,XX,+11,+19+21/50, 4 No metaphase 0
XX,+11,+19,+20,+21
9 46,XY,t(1;7)(p32;q35),+11(p11) 11 46,XY,t(1;7)(p32;q35)+11(p11) 6
10 No result 38 No result 10
11 45,XX,- 8,-22,+ mar 6 No result 5
12 No metaphase 0 No metaphase 0
13 45,X,-Y,t(8;21)(q22;q22) 12 No result 7
14 No result 24 46,XX 15
15 No metaphase 0 No result 7
16 46,XY,t(9;22)(q34;q11) 16 46,XY,t(9;22)(q34;q11) 11
17 46,XY 10 46,XY 8
18 46,XY,t(9;22)(q34;q11) 15 46,XY,t(9;22)(q34;q11) 10
19 46,XX 10 46,XX 10
20 46,XY 10 46,XY 8
21 46,XX,del (11)(q23) 15 46,XX, del(11)(q23) 13
22 46,XY,t(15;17)(q22;q12) 11 No result 3
23 47,XY,+dm/46,XY,-7, 7 No result 8
+der(1;7)(q10;p10)
24 46,XX,t(9,22)(q34;q11) 10 46,XX,t(9,22)(q34;q11) 8
25 46,XY,t(9,22)(q34;q11) 10 46,XY,t(9,22)(q34;q11) 8
At least 15 metaphases were analyzed (range: 0-38). “No result” indicates a result not obtained due to poor
morphology or paucity of metaphases. “No metaphase” indicates a complete absence of metaphases.
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performed by the Student t-test and paired t-
test with a confidence interval of 5%
(P < 0.05).
For evaluation of cell proliferation, mi-
totic index was calculated as reported by
Tsuchiya et al. (12). Three slides from each
culture were prepared for this scoring. Cyto-
genetic analysis was successful in 76% of
fresh cell cultures. In the remaining 24%,
results could not be obtained due either to
poor banding or fuzzy chromosomes, while
results were obtained for 52% of cryopre-
served samples (P < 0.05). The mitotic index
for fresh cultures stimulated with GM-CSF
did not differ from that for cultures cryopre-
served with GM-CSF (P = 0.08), indicating
that GM-CSF did not exert a proliferative
effect on these cells (Table 1). In addition,
there was no difference between cultures A
and B (with and without GM-CSF) with
respect to mitotic index. The morphological
aspect of the chromosomes in fresh and cryo-
preserved cells was subjectively the same.
Chromosomal abnormalities were the same
in both cultures (Table 2). There was a sig-
nificant difference in mitotic index between
pre-freezing and post-freezing A cultures
(P = 0.007) and between pre-freezing and
post-freezing B cultures (P = 0.000), show-
ing that the mitotic index was reduced by
cryopreservation.
The average cell viability before and af-
ter freezing was 98.8 and 78.5%, respec-
tively (P < 0.05). The average frozen cell
concentration was 25 × 106 cells/ml and the
average volume was 12.7 ml (range: 1.2-38
ml). There was no correlation between dis-
ease and viability.
Freezing is an insult to the cell and the
physical disruption that takes place leads to
intracellular chemical changes (13). The cryo-
preservation method used here was very
simple, combining DMSO and hydroxyethyl
starch as cryoprotectant agents. DMSO  pro-
tects the cell as a chemical agent and acts by
reducing electrolyte concentration in the re-
sidual unfrozen solution and around the cell
at any given temperature (14). The ice crys-
tal formation inside the cell during the freez-
ing procedure is probably the harmful key
event for the cells (13). Based on this,
Massumoto et al. (15) developed a new cell
cryopreservation method using a controlled
rate freezing system. The cells were frozen
in a controlled rate freezer chamber at the
following rate: -1ºC/min from room temper-
ature to -10ºC, then -10ºC/min down to
-80ºC. All patients had marrow engraftment
after infusion of these hematopoietic stem
cells. The cited investigators concluded that
this method could cause less damage to cells.
We did not evaluate the controlled rate freez-
ing method because our intention was to
obtain karyotyping results using a simple
and inexpensive freezing method.
The cell viability test showed a signifi-
cant difference between the pre- and post-
freezing period (98.8 and 78.5%; P < 0.05),
as also reported by others (4,16), indicating
that less than 25% of the cells are lost in the
freezing-thawing process. Cytogenetic anal-
ysis was successful in 52% of frozen samples
(P < 0.05) and in 76% of fresh samples (P <
0.05). Cryopreservation led to a decrease in
cell viability and hence in mitotic index.
Some possible explanations for this result
are: 1) an inhibitory effect of DMSO on
spontaneous cell proliferation as observed
by Limaye (17), besides the fact that freezing
is also an important insult to the cells (13),
and 2) the formation of oxygen free radicals
(17). Free radical damage has been impli-
cated as one of the causes of loss of cell
viability during or immediately after freez-
ing (13). In 1997, Limaye (17) reported a
new cryopreservation method in which the
poor growth factor responsiveness of cryo-
preserved bone marrow cells was consider-
ably restored when the cells were frozen in
the presence of three antioxidants: ascorbic
acid, catalase and L-tocopheryl acetate.
Samples cryopreserved in the presence of these
antioxidants showed a statistically significant
increase in both late CFU-GM (colony-form-
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ing unit-granulocyte-macrophage) and early
progenitors as compared to those cryopre-
served in the absence of antioxidants. We
did not use these antioxidants because our
objective was to obtain the best results pos-
sible without using expensive equipment and
chemicals. Nevertheless, additional studies
using these antioxidants are needed.
There was a statistically significant dif-
ference in mitotic index between pre- and
post-freezing A cultures (P = 0.007) and pre-
and post-freezing B cultures (P = 0.000),
confirming that mitotic index was reduced
by cryopreservation (4,15-17).
In 2001, Bosga-Bouwer et al. (18) stud-
ied the results of karyotyping of fresh and
defrosted bone marrow cells from 11 pa-
tients with acute myeloid leukemia. In 8 of
11 cases, the results were comparable with
respect to the quality of abnormal meta-
phases. In the present study, whenever a
comparison was possible (sufficient meta-
phases for analysis), chromosome morphol-
ogy was similar in fresh and frozen cell
cultures. We obtained good agreement of re-
sults for acute and chronic myeloid leukemia.
It is well known that the karyotype of
acute myeloid leukemia cells is easier to
obtain than the karyotype of acute lympho-
blastic leukemia cells (2). Indeed, while
myeloid cells pose few technical problems
to the cytogeneticist to obtain good chromo-
some spreads and morphology, acute lym-
phoblastic leukemia cells frequently present
poor spreading, fuzzy chromosomes and in-
distinct bands (4). In addition, it has been
shown that acute lymbloblastic leukemia cells
do not resist ex vivo too long, with immedi-
ate attention or a direct method being neces-
sary to detect some abnormal clones (4). We
obtained the same results in 2/3 (67%) of our
acute lymbloblastic leukemia cases before
and after freezing. These results show that
this cryopreservation method is feasible and
reliable.
We did not find a significant difference
in the proliferative effect of GM-CSF be-
tween fresh and frozen cells. In 1997, Limaye
(17) reported a better response to GM-CSF
when ascorbic acid, catalase and L-tocoph-
eryl acetate were added to cryopreserved
cells, while Wang et al. (19) in 2001 demon-
strated that no single hematopoietic growth
factor was effective when used alone for
stimulating the ex vivo expansion of 50 um-
bilical cord blood samples. Thus, it seems
that GM-CSF is not an important stimulating
factor for an increase in mitotic index, as
demonstrated here. We did not find a differ-
ent morphological aspect of karyotype anal-
ysis with the use of GM-CSF.
Brazil is a country of continental dimen-
sions and although hematological assistance
is available in many places throughout the
country, there are few places where impor-
tant complementary methods such as chrom-
osomal analysis are available. Thus, we be-
lieve that if a low-cost, feasible and reliable
cryopreservation method such as that re-
ported here were introduced as routine,
samples could be sent from distant places to
core facilities and hematological patients
would benefit from karyotyping. The results
of the present study show that cytogenetic
analysis of cryopreserved bone marrow cells
can be a reliable alternative to fresh cells in
specific situations, notwithstanding the re-
duced viability and lower percent of success-
ful analysis that are associated with freezing.
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